Anrikefon - Sichuan Haisco Pharmaceutical
Alternative Names: HSK-21542Latest Information Update: 29 Sep 2025
At a glance
- Originator Sichuan Haisco Pharmaceutical
- Class Antiemetics; Antipruritics; Opioid analgesics; Peptides; Skin disorder therapies; Small molecules
- Mechanism of Action Opioid kappa receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Postoperative pain
- Preregistration Pruritus
- Clinical Phase Unknown Postoperative nausea and vomiting
Most Recent Events
- 22 Sep 2025 Haisco Pharmaceutical initiates enrolment in a phase III trial for Postoperative pain in China (Parenteral) (NCT07186426)
- 15 May 2025 Registered for Postoperative pain in China (Parenteral)
- 17 Mar 2025 Adverse event data from the preclinical trial in Postoperative pain was released by Sichuan Haisco Pharmaceutical